Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination
Yu Sawada(Yokohama City University), Tetsuya Nakatsura(Unknown), Shoichi Mizuno(Shizuoka Cancer Center), Itaru Endo(Yokohama City University), Toshiaki Yoshikawa(Aichi Cancer Center), Daisuke Nobuoka(Fukuyama City Hospital), Chisako Yamauchi(National Cancer Center Hospital East), Mari Takahashi(Chiba Cancer Center), Satoshi Fujii(National Cancer Center Hospital East), Shuichi Mitsunaga(National Cancer Center Hospital East)
Cited by 30
Related Papers
Randomized clinical trial of adjuvant gemcitabine chemotherapy <i>versus</i> observation in resected bile duct cancer
|British journal of surgery|2018|401
Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
|Clinical Cancer Research|2012|304
Clinical practice guidelines for the management of biliary tract cancers 2015: the 2<sup>nd</sup> English edition
|Journal of Hepato-Biliary-Pancreatic Sciences|2015|300
Clinical practice guidelines for the management of biliary tract cancers 2019: The 3rd English edition
|Journal of Hepato-Biliary-Pancreatic Sciences|2020|235
Surgical outcomes of gastroenterological surgery in Japan: Report of the National Clinical Database 2011‐2017
|Annals of Gastroenterological Surgery|2019|210